List of Biologics Companies in New York - 119

22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Aethon takes a novel approach to fighting cancer, creating custom antibody therapeutics that unite immunotherapy and targeted therapy.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

Developing Novel Therapies for Multiple Sclerosis

Beyond Air Inc. is a commercial stage medical device and biopharmaceutical company focused on harnessing nitric oxide therapy. The company is built on a legacy of innovation and is revolutionizing nitric oxide therapy. Beyond Air Inc. has experience and leadership that go beyond, with a team of industry professionals dedicated to advancing medical treatment. For more information, visit https://www.beyondair.net/

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Our unique modular closure system is called the Xvivo System model X2. Many people dismiss it as simply another isolator. It does look like one and has glove access where necessary in the workflow. However, unlike isolators it has extensive plug-and-play modularity so it can enclose any production process. Less obvious but just as important, it can easily be reconfigured to quickly accommodate any changes or improvements to the process such as new equipment or automation, or as you need to scale

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Cambrian Bio is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.

Channavix Therapeutics, LLC is developing a portfolio of novel, non-addictive, non-opioid analgesics that provide multi-week pain relief with local administration. The business and scientific team that has been assembled for Channavix has a long history of working in the field of pain management and drug development. Channavix is dedicated to the discovery of novel therapeutics for neurological disorders such as pain, with a mission to improve patient outcomes and address the global opioid problem.

Chimerna Therapeutics is a biotech company focused on RNA therapeutics. Their platform for generating circular RNA overcomes the major limitations of RNA therapeutics, such as stability and abundance.

Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.

CLS Therapeutics is a biopharmaceutical firm that provides transformative gene therapy solutions for cancer patients.

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

https://www.comprehensivecellsolutions.com/contact/ Comprehensive Cell Solutions (CCS), is a business division of the New York Blood Center Enterprises, created to meet the needs of academic institutions, hospitals, biotech, pharmaceutical and startups organizations to launch new products, services, and perform clinical trials. CCS makes clinical and research challenges simple by leveraging NYBCe’s world-class expertise and experience in clinical trials management, regulatory and accreditation history. To date, CCS has: • Collaborated with early stage companies to co-develop innovative products. • Collaborated with diverse business entities and academic institutions to manage clinical trials, assist with budget, contracts, IRB submission, FDA submission, and invoicing. • Initiated and participated in national and international clinical trials. Comprehensive Cell Solutions seeks to expand its loyal customer base by offering an extensive suit of R&D products and services that have been designed to seamlessly facilitate partnerships, innovation support, and joint-ventures. CCS is quickly on its way to becoming a world renown pioneer of research and development in new generations of blood and cell-based therapies that address critical, unmet patient needs. Did You Know? • The CCS team has reviewed and overseen hundreds of research projects, preclinical and clinical studies? • CCS is a subject recruitment expert with access to hundreds of thousands of normal, healthy donors for most clinical trial studies? • CCS provides consultation on FDA requirements, certification and 510(K) application, technical performance, and improvements and adaptations to meet and exceed FDA certification requirements? • CCS has a plethora of ‘Ready to Ship’ and ‘Made to Order’ products available with one-click of a button? Contact us now to learn more about how we can support your endeavors https://www.comprehensivecellsolutions.com/contact/

CryptoMedix is a biotech company in the field of Oncology, developing highly innovative treatments for cancer.

Curia is a Contract Development and Manufacturing Organization with over 30 years of experience, an integrated network of 25 global sites and 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com ************************************************** ⚠️NOTICE: Please Be Aware of False Employment Opportunities ************************************************** Please be aware there has been reported fraudulent activity within our industry regarding false offers being made to applicants and requests for personal information from individuals or organizations posing as company representatives. Any applicant who applies to Curia must submit their application through Curia’s career page at https://careers.curiaglobal.com. Applicants will only receive communication, including offer letters, from a curiaglobal.com email address. Please be aware that recent scams used email addresses that are similar to Curia addresses or use other public domain addresses such as gmail.com, yahoo.com and aol.com. Please confirm the sender’s email address prior to sharing your information.

Embleema's software platform brings precision medicine sooner to patients by collecting and generating regulatory-grade evidence. Our platform natively unifies clinical, molecular and real-world data and is the sole one used by the FDA for its regulatory evaluation of health products involving genomic datasets. The protocols and algorithms contained in our platform are also the basis for future CDISC standards for cell and gene therapies. The FDA also uses our platform to produce regulatory grade genomic sequences for SARS-CoV-2 and other microbial pathogens (project ARGOS). In addition to the FDA, our platform powers the Lupus Landmark Study, the largest clinical study for lupus in the world, the Human Epilepsy Projects and tens of other clinical studies for pharmaceutical companies, biotechs and patient groups. More than half of the top 10 Investigational sites in the US use our platform: John Hopkins, NYU, UCSF, Yale, UPenn, Washington University in St Louis, Cornell and many others also such as Mayo Clinic, Yale, Georgetown.

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

EpiBone is a revolutionary bone reconstruction company that allows patients to "grow their own bone". EpiBone's pioneering technology utilizes a scan of the patient's bone defect and the patient's own stem cells to construct and cultivate a defect-specific autologous-like bone graft. EpiBone is strategically positioned to provide a superior bone graft that will provide exact defect repair, a simplified surgical procedure, improved bone formation and regeneration, and shorter recovery times, without the complications of foreign body implantation, to the over 900,000 patients who undergo bone-related surgeries each year.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

For-Robin Therapeutics, (F-R), is an antibody immunotherapy company, founded in 2012 by Dr. Kate Rittenhouse-Olson. The company name is in honor of Robin Quataert, the Founder’s sister, who died at age 31 of estrogen and progesterone receptor negative breast cancer. For-Robin’s primary mission is treating breast cancer patients. Our proprietary technology (the monoclonal antibody JAA-F11 and humanized variants of it) targets all breast cancer cell subtypes including triple negative breast cancer which currently has no targeted therapy. In addition, this technology should be applicable to colon, prostate, and bladder carcinoma patient populations. For-Robin plans to bring its core humanized JAA-F11 technology as an adjunct therapy to patient populations as quickly, safely and efficaciously as possible.

FOXG1 Research Foundation (FRF) is a US-based 501(c)(3) not-for-profit dedicated to accelerating research to find a cure FOXG1 syndrome. Previously called Brain Factor 1, FOXG1 is one of the first and most fundamental genes formed during brain development. Most children with FOXG1 syndrome cannot walk, talk, crawl, or take care of their most basic needs; most have a feeding tube, most undergo major surgeries, and most suffer from life-threatening seizures. Many leading neuroscientists believe that FOXG1 holds the key to unlocking many brain disorders that affect millions of people including autism, schizophrenia, Alzheimers and brain cancers. They also believe FRF can get to human clinical trials in three to five years. The FOXG1 Research Foundation was founded by FOXG1 moms in 2017 with the support of a worldwide team of FOXG1 parents. FRF is quickly becoming known in the biotech arena as a Patient Organization making tremendous strides. FRF raised more than one million dollars in less than one year and has successfully funded six major research projects fostering the most comprehensive study of FOXG1 to-date. The potential to improve millions of lives is tremendous. The time is now. Join us to pioneer some of the most ground-breaking research in human history. 1 www.foxg1research.org

FREZENT is a preclinical stage oncology therapeutics company based in New York. The company is developing bispecific antibodies and antibody-drug conjugates for targeting dormant cancer cells that may cause cancer recurrence. Dormant cancer cells are tiny residual parts of a tumor, that was not completely eliminated by the treatment. They can remain in the body undetectable for a period of time but eventually these cells can transform back into a fast growing tumor. FREZENT is developing a novel cancer treatment that will block the reactivation of dormant cancer cells. To achieve this goal, we are developing novel cancer therapeutic that can neutralize metabolic factors supplied tumor microenvironment to support the dormant cancer cells. Being in a dormant state, cancer cells depend on these external supplies, and thus blocking this supply will starve cancer cells and induce cell death. Join us in our mission to ensure the future where long-lasting remission is the reality for ALL cancer patients.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Hemogenyx Pharmaceuticals PLC is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.

The Interactive Advertising Bureau (IAB) empowers the media and marketing industries to thrive in the digital economy. Its membership comprises more than 700 leading media companies, brands, agencies, and the technology firms responsible for selling, delivering, and optimizing digital ad marketing campaigns. The trade group fields critical research on interactive advertising, while also educating brands, agencies, and the wider business community on the importance of digital marketing. In affiliation with the IAB Tech Lab, IAB develops technical standards and solutions. IAB is committed to professional development and elevating the knowledge, skills, expertise, and diversity of the workforce across the industry. Through the work of its public policy office in Washington, D.C., the trade association advocates for its members and promotes the value of the interactive advertising industry to legislators and policymakers. Founded in 1996, IAB is headquartered in New York City.

iCell Gene Therapeutics is developing Chimeric Antigen Receptor (CAR) engineered cells with improved functional properties and expanded applicability. We are a clinical stage company focused to demonstrate clinical proof of concept for unique, patent protected, targets and strategies. Our pipeline includes multiple additional first in man CAR strategies to target hematological cancers, non-hematological cancers and autoimmune disorders.

Ichnos Sciences is a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology and disease-centric therapies.

ICPD began by integrating pre-clinical and clinical data through modeling and simulation to improve how antibiotic resistance is defined in the clinical microbiology laboratory. ICPD then ignited the use of PK-PD-based dose regimen selection that now ensures optimal patient drug exposures and thus, an increased likelihood of successful response during the antibiotic development process. ICPD educates drug regulators and pharmaceutical and biotechnology companies on PK-PD-based strategies to make certain safe and effective antibiotics are available to thwart the growing threat of antibiotic-resistance. ICPD Technologies has used the foundation laid by ICPD and others to develop a mobile device application that provides PK-PD education to clinicians. Through the revolutionary PK-PD Compass, ICPD Technologies will carry out a mission to educate clinicians and improve antibiotic stewardship efforts worldwide.

ILGEN is a biopharmaceutical company propelling medicine on novel proprietary biotechnology. They are the first-in-class, naturally occurring LAG3 checkpoint inhibitor.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.

Immunyx Pharma is focused on changing the landscape of immune modulation by targeting neutrophil toxicity in numerous chronic diseases. The company was built by world leaders in neutrophil biology and nanoparticle delivery to use a targeted neutrophil nanoparticle platform (TENNs) to solve the significant issues in neutrophil therapy. While big pharma has invested heavily in neutrophil targeted drugs, they have failed to bring solutions to the clinic due to the danger of causing neutropenia and the difficulty of modulating such a large & dynamic population of cells. Our TENN platform is intended to manipulate neutrophil toxic behavior without destroying their disease fighting function, while bringing a concentrated payload of drug to all neutrophils throughout the body with a long bioavailability. We are currently focusing on applying our platform to modulate neutrophil activity in cancer and inflammatory disease.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

The Indaptus Goal is Simple: to Cure Disease With the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.

ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. The lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. Clinical Trials are being executed globally with a particular focus on improving patient health post-transplantation.

Kinevant Sciences is on a mission to transform the lives of people living with rare inflammatory diseases through high-impact medicine. Kine is a word from Ancient Greece meaning “to move” or “set in motion,” which defines our purpose of moving safe and accessible therapeutics forward, so patients feel empowered to take back full control of their lives. Our approach combines patient-forward thinking, scientific rigor and clinical excellence to overcome some of the most deep-rooted barriers to treatment within underserved populations by delivering disease-modifying therapeutics that are safe, well tolerated and easily accessible. Our lead product candidate, namilumab, is an investigational monoclonal antibody being developed for treatment of sarcoidosis. Namilumab has the potential to address the underlying disease pathology by targeting GM-CSF, a key pro-inflammatory cytokine and growth factor implicated in the pathogenesis of sarcoidosis and other inflammatory disorders. Kinevant has initiated two actively enrolling clinical trials to investigate namilumab as a potential new treatment for sarcoidosis to significantly improve patients’ overall quality of life.

Lake Immunogenics was founded in 1985. Animal health and ethical treatment are our passions. Our benchmark plasmapheresis process allows large volume production of polyclonal antibodies without compromising the donor animal. From initial offerings of custom polyclonal antibodies, the business expanded to the equine therapeutic market. RhodococcusEqui Antibody (Pneumomune-Re), Equine IgG (HiGamm Ð equi) and Plasmune plasma products for foal health are the cornerstones of our therapeutic products. Today, the facilities include research and development laboratories, production rooms with walk in freezer capacity and a 155 acre farm that is home to closed herds of horses, steer, llamas, and goats. Lake Immunogenics continues to provide custom polyclonal antibodies and is select agent registered with the CDC. Our veterinary therapeutics have expanded beyond equine products to include plasma products for camelids, bovine and goats. Lake Immunogenics also provides high quality animal blood products as starting material for further biologics manufacturing and for research and development. In 2011, Lake Immunogenics Inc. added large animal preclinical studies to our service offerings. In 2013 we began providing accredited housing for long term study animals. Bovine plasma was introduced in 2015

Leal Therapeutics is a biopharmaceutical company that focuses on developing novel therapeutics for patients with major disorders of the central nervous system.

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

LineaRx, an Applied DNA Sciences, Inc. company (NASDAQ: APDN) delivers enzymatically-produced LinearDNA™ as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (“PCRâ€?) based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences.

MABLYTICS is a biotechnology company that specializes in developing immunotherapies using a novel target with applications in cancer research.

Biotech company delivering innovative precision biologics for patients with advanced, metastatic cancers

Unleashing the Power of Antibodies to Fight Cancer: We aim to unlock the full potential of antibodies and their applications, enabling breakthrough precision medicines for a wide range of diseases.

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases.

Mercer University is a higher education institution offering a variety of academic programs and degrees.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

Diagnostics We build innovative diagnostic and monitoring tools that empower people to make better decisions about their health. Drug Discovery We translate early-stage research into customized RNAi and CRISPR Cas9 animal and cell models to accelerate drug development. Therapeutics We identify and validate new drug targets, unleashing the commercial potential of RNAi to benefit people on a global scale. Established in 2010 to harness the power of RNAi and genetic engineering technologies developed by our founders in the labs of the world's leading experts at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and Harvard Medical School, Mirimus creates innovative research and clinical technologies to address health issues on a global scale. Today, Mirimus markets multiple unique and high-value drug discovery and diagnostic products and services, and is advancing a pipeline of therapeutic candidates in partnership with leading biopharma companies to create novel high-impact health care solutions that benefits society on a global scale. Mirimus' ability to leverage its cutting-edge science and proprietary technology platforms to rapidly create new, affordable technology and products at scale is core to the way we work. We embrace diversity and creativity and have a proven track record of innovative problem solving—which led to our recognition as a $1M grand prize winner of the XPRIZE competition by developing a radically affordable, rapid, non-invasive methodology for mass COVID-19 testing—driving us to make better drugs and detect disease earlier. At Mirimus, our ingenuity, respect for our colleagues' ideas and creativity, executional agility, and a commitment to global health equity combine to create a unique culture of innovation that delivers measurable progress.

Mispro's contract vivarium (CV) solution offers emerging, mid-sized, and even mature biopharma companies access to state-of-the-art vivarium research facilities and laboratory animal services for preclinical drug discovery and development. Our space plus services model enables founding scientists and research teams to keep in in vivo rodent studies in-house without having to incur the costs and operational complexities of internalizing a vivarium facility.

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. WHO WE ARE We are compassionate collaborators—38,000 strong—working to heal, teach, and advance medicine in New York City and throughout the world. WHAT WE BELIEVE We believe in challenging the status quo. Forging a new pathway in clinical excellence is only possible by putting the patient at the center of the experience. WHY WORK WITH US Here, innovation is valued and collaboration is integral. Mount Sinai is full of friendly, helpful people who share a common devotion to delivering exceptional patient care. Yet we’re as diverse as the city we call home—culturally, ethnically, in outlook and lifestyle. When you join us, you become part of Mount Sinai’s unrivaled record of achievement, education, and advancement as we revolutionize healthcare together.

NeoMatrix Therapeutics, Inc. is a clinical-stage company dedicated to discovering and developing novel therapeutic agents for the treatment of serious burn injuries. They focus on developing bioactive peptides that prevent injury progression and rescue tissue from further damage.

Nephrogen is a therapeutics company developing transformative medicines for kidney disease. Their initial focus is on gene therapy for autosomal dominant polycystic kidney disease (ADPKD).

Neural Stem Cell Institute is a regenerative medicine company that focuses on developing stem cell therapies for diseases of the nervous system.

NILO Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.

NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective therapeutics for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.​

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Oncolyze is developing therapeutics that exploit a novel mechanism of action for the targeted and selective lysis of cancer cells and cancer stem cells.

OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp completed a $25m seed round from investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, and AIHC Capital. OnCusp has offices in New York and Shanghai.

Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. Read more: http://www.oramed.com/investors/corporate-presentation Watch: https://www.youtube.com/watch?v=5qChxTDV9eg Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/

Ordaos is a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins. Their mission is to help biopharma partners deliver life-saving treatments by creating bespoke mini-proteins to aid drug hunters.

OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center. Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes. These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to “harness the editing process” to create therapies for a number of disease states. OyaGen’s initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that: -Identified an Editing Enzyme present in immune system -Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle -Demonstrated that allowing this Editing Enzyme to function halts HIV OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states. OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.

Our global associates are unified by a singular drive: to take on our customers’ biggest challenges. To solve the critical problems that stand in the way of advancing health, safety and the environment. Where others see something that can’t be done, we jump in fully committed to do it. We push the limits of science and technology. We redefine partnership through deeper, more meaningful collaboration. It’s how we’ve approached our calling since 1946. And why today you’ll find our filtration, separation and purification solutions at work in so many places. From life-saving gene therapies to airplane engines. Hydraulic systems to injectable medications. Scotch. Smartphones. OLED screens. Paper. Everyday Pall is there, helping protect critical operating assets, improve product quality, minimize emissions and waste, and safeguard health. No matter what, no matter where, we innovate and collaborate to deliver the one thing our customers need most: The unsolvable, solved. More here: http://www.pall.com. ******* Pall Corporation is proud to be part of Danaher. Danaher’s science and technology leadership puts Pall’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Phoenix Nest Biotech is a biotechnology company that focuses on treating Sanfilippo Syndrome by collaborating with leading academics and utilizing licensed key technologies.

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

Prevail Therapeutics was acquired by Eli Lilly and Company. At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.

Profacgen offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy,process development, cGMP manufacturing, and analytical development.

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

RegenLab is recognized as a global leader in medical biotechnologies, specializing in cellular therapies, manufactured in the USA. RegenLab is at the forefront of innovation, with an expertly designed medical device for the preparation of platelet rich plasma from the patient's own blood. Regen® A-PRP® is FDA cleared and developed with a focus on product quality, patient safety, and preparation efficiency. Our patient-centered technology has led to over one million treatments worldwide using RegenLab products. As we look to the future, we are committed to guiding new standards for emerging categories within the field of regenerative medicine.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone, and was named one of DARPA’s “Biotech Startups of the Future” one year after opening its operations. The company was co-founded by David D. Ho, MD (Time magazine's "Man of the Year" in 1996 and recipient of the Presidential Citizens Medal) and Yaoxing Huang, PhD, visionary scientists affiliated with the Aaron Diamond AIDS Research Center and Professors at Columbia University Medical Center. RenBio is backed by the Bill & Melinda Gates Foundation, DARPA, and a syndicate of private investors, and is headquartered at the Alexandria Center® for Life Science in New York City.

Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.

Rocket Pharmaceuticals (NASDAQ: RCKT), Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based and adeno-associated virus (AAV) therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Our pipeline of SPEARs™ (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. We are advancing our lead programs, ST316, a first-in-class antagonist of β-catenin, and lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, through Phase 2 clinical trials. Please engage with us on this platform to learn more!

Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs.

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

The Integrated Genomics Operation (IGO) at Memorial Sloan Kettering (MSK) is a collaborative core facility dedicated to generating high-quality genomics data for basic, translational, and clinical research projects. The core is focused on Illumina Next-Generation Sequencing (NGS) while also providing comprehensive genomics services including pathological review of tissue samples, fragment analysis, Sanger sequencing, and much more.

Patients around the world are struggling with debilitating back pain, trying to avoid invasive surgeries and the potential of opioid addiction. Spine Biopharma has developed a non-surgical solution that will remove pain and restore functionality, without having to use opioids.

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes Elzonris®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

This page is no longer active or monitored. We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us! ⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀ ==== Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of novel therapies for patients with rare conditions and other diseases. Through our proprietary computing and data platforms, scientific expertise and diverse company portfolio, Sumitovant has supported development of multiple FDA-approved products and a robust pipeline of early-through late-stage investigational assets addressing unmet need in pediatrics, urology, oncology, women’s health, specialty respiratory and infectious diseases. Sumitovant is a wholly owned subsidiary of Sumitomo Pharma. Please visit our website sumitovant.com for more information on Sumitovant and our portfolio.

Dynamic therapeutics immuno-oncology startup in NYC. Synthis’s team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

TFC Therapeutics is developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. We’re blending early-stage research with innovative platform design to develop next-generation treatments to eliminate the most resilient cancers and put an end to their recurrence before it begins.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

TheraSource is a growing biotech company located in the Greater New York area. Our mission is to develop novel anti-inflammatory therapeutics for the treatment of human diseases. TheraSource is currently focused on the development of newly-discovered molecules to treat patients with ischemic acute kidney injury (AKI) and acute radiation injury. TheraSource's R&D unit resides at The Feinstein Institute for Medical Research, which is equipped with a state-of-the-art preclinical testing facility. Our research team currently consists of 9 scientists with MD or PhD degrees in multidisciplinary areas, including protein chemistry, cell biology, immunology, pathophysiology, and clinical medicine. The company possesses 14 utility patents covering 5 molecules to treat selected inflammatory human diseases.

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

University at Buffalo Center for Entrepreneurial Leadership is an education institution that offers entrepreneurship and leadership development programs.

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

Verra Therapeutics is a privately held company near Ithaca NY, that was founded in 2017 with a mission of transforming the treatment of protease-driven diseases using an innovative small protein platform. Verra is developing preclinical drug candidates for Chronic Bronchitis, Acute Lung Injury and Acute Kidney Injury by adapting nature’s highly evolved design for each target protease. Dr. Christopher Prince brings decades of leadership experience to the team in managing technology companies through biotech and pharmaceutical development. Dr. Marcia Moss has a comprehensive background in drug discovery and development and is a thought leader on proteases as disease targets. Verra’s goal is to create novel, selective and impactful drugs for patients with major unsolved medical illnesses.

Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.

Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

北京东方百泰生物科技有限公司 is a pharmaceuticals company based out of 北京, 北京, China.